Mostrando 81 - 100 Resultados de 128 Para Buscar 'Lama (person)', tiempo de consulta: 3.34s Limitar resultados
  1. 81
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings
  2. 82
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The use of video job-aids to improve the quality of seasonal malaria chemoprevention delivery
  3. 83
    por Sala‐Vila, Aleix, Guasch‐Ferré, Marta, Hu, Frank B., Sánchez‐Tainta, Ana, Bulló, Mònica, Serra‐Mir, Mercè, López‐Sabater, Carmen, Sorlí, Jose V., Arós, Fernando, Fiol, Miquel, Muñoz, Miguel A., Serra‐Majem, Luis, Martínez, J. Alfredo, Corella, Dolores, Fitó, Montserrat, Salas‐Salvadó, Jordi, Martínez‐González, Miguel A., Estruch, Ramón, Ros, Emilio, Pérez‐Heras, A., Viñas, C., Casas, R., de Santamaría, L., Romero, S., Sacanella, E., Chiva, G., Valderas, P., Arranz, S., Baena, J.M., García, M., Oller, M., Amat, J., Duaso, I., García, Y., Iglesias, C., Simón, C., Quinzavos, Ll., Parra, Ll., Liroz, M., Benavent, J., Clos, J., Pla, I., Amorós, M., Bonet, M.T., Martin, M.T., Sánchez, M.S., Altirriba, J., Manzano, E., Altés, A., Cofán, M., Valls‐Pedret, C., Doménech, M., Gilabert, R., Bargalló, N., González, R., Molina, C., Márquez, F., Babio, N., Sorli, M., García Roselló, J., Diaz‐López A, A., Martin, F., Tort, R., Isach, A., Costa, B., Cabré, J.J., Fernández‐Ballart, J., Ibarrola‐Jurado, N., Alegret, C., Martínez, P., Millán, S., Piñol, J.L., Basora, T., Hernández, J.M., Toledo, E., Buil‐Cosiales, P., Ruiz‐Canela, M., Sanjulián, B., Díez‐Espino, J., Extremera‐Urabayen, V., García‐Arellano, A., Zazpe, I., Basterra‐Gortari, F.J., Goñi, E, Razquin, C., Serrano‐Martínez, M., Bes‐Rastrollo, M., Gea, A., Martínez‐Lapiscina, E.H., Nuñez‐Córdoba, J.M., Arroyo‐Azpa, C., García‐Pérez, L., Villanueva‐Tellería, J., Cortés‐Ugalde, F., Sagredo‐Arce, T., García de la Noceda‐Montoy, Mª D., Vigata‐López, Mª D., Arceiz‐Campo, Mª T., Urtasun‐Samper, A., Gueto‐Rubio, Mª V., Churio‐Beraza, B., Lamuela‐Raventós, Rosa M., Castellote‐Bargallo, A.I., Medina‐Remón, A., Tresserra‐Rimbau, A., Carrasco, P., Ortega‐ Azorín, C., Asensio, E.M., Osma, R., Barragán, R., Francés, F., Guillén, M., González, J.I., Saiz, C., Portolés, O., Giménez, F.J., Coltell, O., Guillem‐Saiz, P., Quiles, L., Pascual, V., Riera, C., Pages, M.A., Godoy, D., Carratalá‐Calvo, A., Martín‐Rillo, M.J., Llopis‐Osorio, E., Ruiz‐ Baixauli, J., Bertolín‐Muñoz, A., Salaverría, I., del Hierro, T., Algorta, J., Francisco, S., Alonso, A., San Vicente, J., Sanz, E., Felipe, I., Alonso Gómez, A., Loma‐Osorio, A., García‐Valdueza, M., Moñino, M., Proenza, A., Prieto, R., Frontera, G., Ginard, M., Fiol, F., Jover, A., García, J., Covas, M.I., Tello, S., Vila, J., Schröder, H., De la Torre, R, Muñoz‐Aguayo, D., Elosúa, R., Marrugat, J., Ferrer, M., Álvarez‐Pérez, J., DíazBenítez, E., Bautista‐Castaño, I., Maldonado‐Díaz, I., Sánchez‐Villegas, A., Castro, I., Henríquez, P., Ruano, C., Ortiz, A. P., Sarmiendo de la Fe, F, Simón‐García, C., Falcón‐Sanabria, I., Macías‐Gutiérrez, B., Santana‐Santana, A.J., Gomez‐Gracia, E., Fernández‐Crehuet, J., Benítez Pont, R., Bianchi Alba, M., Wärnberg, J., Gómez‐Huelgas, R., Martínez‐González, J., Velasco García, V., de Diego Salas, J, Baca Osorio, A., Gil Zarzosa, J., Sánchez Luque, J.J., Vargas López, E., Ruiz‐Gutierrez, V., Jurado Ruiz, E., Montero Romero, E., García García, M., Lapetra, J., Leal, M., Martínez, E., Santos, J.M., Ortega‐Calvo, M., Román, P., José García, F., Iglesias, P., Corchado, Y., Mayoral, E., Lama, C., Pintó, X., de la Cruz, E, Galera, A., Soler, Y., Trias, F., Sarasa, I., Padres, E., Figueras, R., Solanich, X., Pujol, R., Corbella, E., Cabezas, C., Vinyoles, E., Rovira, M.A., García, L., Flores, G., Verdú, J.M., Baby, P., Ramos, A., Mengual, L., Roura, P., Yuste, M.C., Guarner, A., Rovira, A., Santamaría, M.I., Mata, M., de Juan, C., Brau, A., Marti, A., Mitjavila, M.T., Portillo, M.P., Sáez, G., Tur, J.
    Publicado 2016
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dietary α‐Linolenic Acid, Marine ω‐3 Fatty Acids, and Mortality in a Population With High Fish Consumption: Findings From the PREvención con DIeta MEDiterránea (PREDIMED) Study
  4. 84
    “…During periods of continuous medication use after initiation (current use), crude incidence rates per 1000 person-years for AMI ranged from 8.7 (aclidinium/formoterol) to 12.4 (LAMA/LABA), for stroke ranged from 4.8 (aclidinium/formoterol) to 7.2 (LAMA/LABA), and for MACE ranged from 13.5 (aclidinium/formoterol) to 19.3 (LAMA/LABA). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
  5. 85
    “…INTRODUCTION: Training in correct inhaler use, ideally in person or by video demonstration, can minimize errors but is rarely provided in clinics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease
  6. 86
    “…After propensity score matching, the incidence rate per 1000 person-years of pneumonia was 93.96 for LAMA (n = 1003) and 136.42 for ICS/LABA (n = 1003) patients (p < 0.001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
  7. 87
    “…Fifty-eight percent of patients had a respiratory hospital admission and 57% had a recorded PHC presentation for a respiratory issue during the study period, with a higher rate of hospital admissions among patients prescribed ICS compared with those on SAMA/SABA or LAMA/LABA without ICS (median rate (per person per year) 0.42 vs 0.21 and 0.21 (p=0.004). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study
  8. 88
    por Azevedo, Flavio, Pavlović, Tomislav, Rêgo, Gabriel G., Ay, F. Ceren, Gjoneska, Biljana, Etienne, Tom W., Ross, Robert M., Schönegger, Philipp, Riaño-Moreno, Julián C., Cichocka, Aleksandra, Capraro, Valerio, Cian, Luca, Longoni, Chiara, Chan, Ho Fai, Van Bavel, Jay J., Sjåstad, Hallgeir, Nezlek, John B., Alfano, Mark, Gelfand, Michele J., Birtel, Michèle D., Cislak, Aleksandra, Lockwood, Patricia L., Abts, Koen, Agadullina, Elena, Aruta, John Jamir Benzon, Besharati, Sahba Nomvula, Bor, Alexander, Choma, Becky L., Crabtree, Charles David, Cunningham, William A., De, Koustav, Ejaz, Waqas, Elbaek, Christian T., Findor, Andrej, Flichtentrei, Daniel, Franc, Renata, Gruber, June, Gualda, Estrella, Horiuchi, Yusaku, Huynh, Toan Luu Duc, Ibanez, Agustin, Imran, Mostak Ahamed, Israelashvili, Jacob, Jasko, Katarzyna, Kantorowicz, Jaroslaw, Kantorowicz-Reznichenko, Elena, Krouwel, André, Laakasuo, Michael, Lamm, Claus, Leygue, Caroline, Lin, Ming-Jen, Mansoor, Mohammad Sabbir, Marie, Antoine, Mayiwar, Lewend, Mazepus, Honorata, McHugh, Cillian, Minda, John Paul, Mitkidis, Panagiotis, Olsson, Andreas, Otterbring, Tobias, Packer, Dominic J., Perry, Anat, Petersen, Michael Bang, Puthillam, Arathy, Rothmund, Tobias, Santamaría-García, Hernando, Schmid, Petra C., Stoyanov, Drozdstoy, Tewari, Shruti, Todosijević, Bojan, Tsakiris, Manos, Tung, Hans H., Umbres, Radu G., Vanags, Edmunds, Vlasceanu, Madalina, Vonasch, Andrew, Yucel, Meltem, Zhang, Yucheng, Abad, Mohcine, Adler, Eli, Akrawi, Narin, Mdarhri, Hamza Alaoui, Amara, Hanane, Amodio, David M., Antazo, Benedict G., Apps, Matthew, Ba, Mouhamadou Hady, Barbosa, Sergio, Bastian, Brock, Berg, Anton, Bernal-Zárate, Maria P., Bernstein, Michael, Białek, Michał, Bilancini, Ennio, Bogatyreva, Natalia, Boncinelli, Leonardo, Booth, Jonathan E., Borau, Sylvie, Buchel, Ondrej, Cameron, C. Daryl, Carvalho, Chrissie F., Celadin, Tatiana, Cerami, Chiara, Chalise, Hom Nath, Cheng, Xiaojun, Cockcroft, Kate, Conway, Jane, Córdoba-Delgado, Mateo Andres, Crespi, Chiara, Crouzevialle, Marie, Cutler, Jo, Cypryańska, Marzena, Dabrowska, Justyna, Daniels, Michael A., Davis, Victoria H., Dayley, Pamala N., Delouvée, Sylvain, Denkovski, Ognjan, Dezecache, Guillaume, Dhaliwal, Nathan A., Diato, Alelie B., Di Paolo, Roberto, Drosinou, Marianna, Dulleck, Uwe, Ekmanis, Jānis, Ertan, Arhan S., Farhana, Hapsa Hossain, Farkhari, Fahima, Farmer, Harry, Fenwick, Ali, Fidanovski, Kristijan, Flew, Terry, Fraser, Shona, Frempong, Raymond Boadi, Fugelsang, Jonathan A., Gale, Jessica, Garcia-Navarro, E. Begoña, Garladinne, Prasad, Ghajjou, Oussama, Gkinopoulos, Theofilos, Gray, Kurt, Griffin, Siobhán M., Gronfeldt, Bjarki, Gümren, Mert, Gurung, Ranju Lama, Halperin, Eran, Harris, Elizabeth, Herzon, Volo, Hruška, Matej, Huang, Guanxiong, Hudecek, Matthias F. C., Isler, Ozan, Jangard, Simon, Jorgensen, Frederik J., Kachanoff, Frank, Kahn, John, Dangol, Apsara Katuwal, Keudel, Oleksandra, Koppel, Lina, Koverola, Mika, Kubin, Emily, Kunnari, Anton, Kutiyski, Yordan, Laguna, Oscar Moreda, Leota, Josh, Lermer, Eva, Levy, Jonathan, Levy, Neil, Li, Chunyun, Long, Elizabeth U., Maglić, Marina, McCashin, Darragh, Metcalf, Alexander L., Mikloušić, Igor, El Mimouni, Soulaimane, Miura, Asako, Molina-Paredes, Juliana, Monroy-Fonseca, César, Morales-Marente, Elena, Moreau, David, Muda, Rafał, Myer, Annalisa, Nash, Kyle, Nesh-Nash, Tarik, Nitschke, Jonas P., Nurse, Matthew S., Ohtsubo, Yohsuke, de Mello, Victoria Oldemburgo, O’Madagain, Cathal, Onderco, Michal, Palacios-Galvez, M. Soledad, Palomöki, Jussi, Pan, Yafeng, Papp, Zsófia, Pärnamets, Philip, Paruzel-Czachura, Mariola, Pavlović, Zoran, Payán-Gómez, César, Perander, Silva, Pitman, Michael Mark, Prasad, Rajib, Pyrkosz-Pacyna, Joanna, Rathje, Steve, Raza, Ali, Rhee, Kasey, Robertson, Claire E., Rodríguez-Pascual, Iván, Saikkonen, Teemu, Salvador-Ginez, Octavio, Santi, Gaia C., Santiago-Tovar, Natalia, Savage, David, Scheffer, Julian A., Schultner, David T., Schutte, Enid M., Scott, Andy, Sharma, Madhavi, Sharma, Pujan, Skali, Ahmed, Stadelmann, David, Stafford, Clara Alexandra, Stanojević, Dragan, Stefaniak, Anna, Sternisko, Anni, Stoica, Augustin, Stoyanova, Kristina K., Strickland, Brent, Sundvall, Jukka, Thomas, Jeffrey P., Tinghög, Gustav, Torgler, Benno, Traast, Iris J., Tucciarelli, Raffaele, Tyrala, Michael, Ungson, Nick D., Uysal, Mete S., Van Lange, Paul A. M., van Prooijen, Jan-Willem, van Rooy, Dirk, Västfjäll, Daniel, Verkoeijen, Peter, Vieira, Joana B., von Sikorski, Christian, Walker, Alexander Cameron, Watermeyer, Jennifer, Wetter, Erik, Whillans, Ashley, White, Katherine, Habib, Rishad, Willardt, Robin, Wohl, Michael J. A., Wójcik, Adrian Dominik, Wu, Kaidi, Yamada, Yuki, Yilmaz, Onurcan, Yogeeswaran, Kumar, Ziemer, Carolin-Theresa, Zwaan, Rolf A., Boggio, Paulo S., Sampaio, Waldir M.
    Publicado 2023
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Social and moral psychology of COVID-19 across 69 countries
  9. 89
    “…RESULTS: From the cohort (n=83 417), we identified 5399 ACS cases during 281 292 person-years of follow-up. Compared with current use of LAMA therapy, current use of LAMA and LABA dual therapy was associated with a higher risk of ACS (OR 1.28 (95% CI 1.13 to 1.44)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?
  10. 90
    “…BACKGROUND: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink
  11. 91
    “…In 2012, only 20.7% of the patients from KNHANES database received long-acting muscarinic agonists (LAMA), whereas 78.7% of the patients from KOCOSS database received LAMA. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function
  12. 92
    “…CONCLUSIONS: GFF MDI demonstrated comparable efficacy and safety outcomes to other LAMA/LABA FDCs. Personalization of treatment choice within the class on the basis of other factors such as patient preference may be appropriate.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
  13. 93
    “…Here, ETHOS data were used to estimate the long-term cost-effectiveness of BGF versus LAMA/LABA and ICS/LABA dual therapies in the United Kingdom. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
  14. 94
    “…This article has an associated First Person interview with the first author of the paper.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Exposure to e-cigarette vapor extract induces vocal fold epithelial injury and triggers intense mucosal remodeling
  15. 95
    por Jiang, Yixuan, Hu, Hao, Leung, Siu-wai
    Publicado 2021
    “…INTRODUCTION: 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting b2-agonists (LABA)(ICS/LAMA/LABA). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
  16. 96
    “…This article has an associated First Person interview with the first author of the paper.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multiscale molecular profiling of pathological bone resolves sexually dimorphic control of extracellular matrix composition
  17. 97
    “…Therapy should be chosen carefully based on individualized assessment, ensuring personalization to the individual needs of the patient.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management
  18. 98
    “…Consistently, the ECM genes LAMA1 and LAMA2, the antiapoptotic gene HSP90, identified in patient databases as hallmarks of invasive ARMS, were higher under perfusion flow at mRNA and protein level. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A perfusion-based three-dimensional cell culture system to model alveolar rhabdomyosarcoma pathological features
  19. 99
    “…The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
  20. 100
    “…PURPOSE: Guidelines recommend the use of triple therapy with an inhaled corticosteroid (ICS), a long-acting β(2) agonist (LABA) and a long-acting muscarinic antagonist (LAMA) to reduce the risk of future exacerbations in symptomatic COPD patients with a history of exacerbations. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
Herramientas de búsqueda: RSS